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Preparing the United States for
High-Sensitivity Cardiac Troponin Assays
Frederick K. Korley, MD,* Allan S. Jaffe, MD†
Baltimore, Maryland; and Rochester, Minnesota
It is only a matter of time before the use of high-sensitivity cardiac troponin assays (hs-cTn) becomes common
throughout the United States. In preparation for this inevitability, this article raises a number of important issues
regarding these assays that deserve consideration. These include: the need for the adoption of a universal no-
menclature; the importance of defining uniform criteria for reference populations; the challenge of discriminat-
ing between acute and nonacute causes of hs-cTn elevations, and between type 1 and type 2 acute myocardial
infarction (AMI); factors influencing the analytical precision of hs-cTn; ascertaining the optimal duration of the
rule-out period for AMI; the need for further evaluation to determine the causes of a positive hs-cTn in non-AMI
patients; and the use of hs-cTn to risk-stratify patients with disease conditions other than AMI. This review elabo-
rates on these critical issues as a means of educating clinicians and researchers about them. (J Am Coll Cardiol
2013;61:1753–8) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.069Recently, clinicians have begun to use the recommended
cut-off values for current generation cardiac troponin (cTn)
assays: the 99th percentile upper reference limit (URL).
Previously, there was reluctance to use these cut-off values
because they are associated with frequent elevations in cTn
from non-acute ischemic heart disease conditions. Thus,
there was a tendency to use cut-off values for troponin that
equated with the prior gold standard diagnosis developed
with less sensitive markers such as creatinine kinase-MB
isoenzyme (CK-MB) or the lowest value at which assay
achieved a 10% coefficient of variation (CV), which was
thought to reduce false-positive elevations. The use of the
99th percentile URL increases the ability of these assays to
detect both acute myocardial infarction (AMI) and struc-
tural cardiac morbidities (1). This change in practice should
not be confused with newer-generation high-sensitivity
assays.
Improvements in the analytic performance of cTn assays
have resulted in superior sensitivity and precision. Improved
sensitivity occurs because of more sensitive antigen binding
and detection antibodies, increases in the concentration of
the detection probes on the tag antibodies, increases in
sample volume, and buffer optimization (2). Assays now are
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accepted September 4, 2012.able to measure 10-fold lower concentrations with high
precision (a CV 10% at the 99th percentile of the URL).
The high-sensitivity cardiac troponin T (hs-cTnT) assay is
already in clinical use throughout most of the world. It is
only a matter of time before high-sensitivity assays are
approved for use in the United States. In preparation for
this, as well as the use of the 99th percentile URL with
contemporary assays, there are a number of important issues
that deserve consideration. Key concepts are included in
Table 1.
Need for a Universally Accepted Nomenclature
The literature is replete with different terms used to refer to
cTn assays. We advocate the use of the term “high-sensitivity
cardiac troponin assays” (hs-cTn) for cTn assays that measure
cardiac troponin values in at least 50% of a reference population
(2,3). This policy we are informed has now been embraced by
the journal Clinical Chemistry. High-sensitivity assays can be
further categorized as well (Table 2).
Ideally, assays should have a CV of 10% at the 99th
percentile value. Assays that do not achieve this level are less
sensitive which protects against false-positive results, and
they can be used (4).
Defining Uniform Criteria
for Reference Populations
There is a lack of consistency in the types and numbers of
subjects that should/can constitute a reference population
(2). Often, participants are included after simple screening
by check list but without a physical examination, electro-
cardiogram, or laboratory testing. At other times, a normal
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uretic peptide value is required.
Imaging to detect structural heart
disease is rarely used. Because it is
known that gender, age, race, renal
function, heart failure, and struc-
tural heart disease, including in-
creased left ventricular (LV) mass
are associated with increased cTn
concentrations (5–7) an assay’s 99th
percentile value depends on the
composition of the reference group.
Thus, the more criteria used, the lower the reference values
(Fig. 1) (5). The appropriate reference value to use clinically
also is far from a settled issue. It might be argued that using
a higher 99th percentile value for the elderly allows com-
parison of the patient to his or her peers, but in raising the
cut-off value, if the increases are caused by comorbidities,
those who are particularly healthy will be disadvantaged (8).
Gender and ethnicity are not comorbidities, and we would
urge that those should be taken into account. It is clear that
regardless of the assay, there will need to be 99th percentile
values for men that are different for women (2). The
reference population for assay validation studies should
ideally be based on demographic characteristics that mirror
the U.S. population and include subjects whose blood
pressure, serum glucose, and creatinine and natriuretic
peptide values are within the normal reference range and
who take no cardiac medications. These subjects should be
free from structural heart disease, documented by echocar-
diography, cardiac magnetic resonance imaging (MRI) or
computed tomography (CT) angiography. Meeting these
criteria will be a major challenge, especially for older
individuals, although some initial studies have been per-
formed (9). A conjoint pool of samples collected with the
support of commercial manufacturers so that all companies
could use the identical patient population for their reference
ranges would be a major advance. One large national effort
Key ConceptsTable 1 Key Concepts
There is a need to develop a universal nomenclature for troponin assays.
There is a need for uniform criteria for selecting reference populations.
The optimal delta criteria for distinguishing between acute and chronic cardiac
injury remain unclear and are likely to be assay-specific.
Distinguishing between type 1 and type 2 AMI is challenging, and more type 2
AMIs will be detected with hsTn assays.
Factors affecting the analytical precision of troponin assays (including how we
collect samples) will become more important with the use of hs-cTn assays.
The optimal duration for ruling out AMI remains unclear; novel approaches to
this issue are being developed.
Elevated hs-cTn, regardless of the cause, has important prognostic implications
and deserves additional evaluation; many cases of chronic elevations can be
evaluated in an outpatient setting.
Hs-cTn can be used to risk-stratify patients with non-ACS cardiovascular
comorbidities.
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
CV  coefficient of
variation
hs  high sensitivity
cTn  cardiac troponin
URL  upper reference
limitACS  acute coronary syndrome; AMI  acute myocardial infarction.would probably be more cost-effective than multiple smaller
efforts.
Regardless of reference values, solitary elevations of hs-
cTn values (99th percentile) will be inadequate for clinical
decision making (10). The exception may be very elevated
values, which are most often caused by MI or myocarditis,
once possible analytical confounding factors are eliminated.
In other circumstances, serial changes in hs-cTn values will
be required to determine whether acute myocardial injury is
present.
Discriminating Between Acute and
Nonacute Causes of hs-cTn Elevations
With the ability to precisely measure small concentrations of
cTn, clinicians will be faced with the challenge of distin-
guishing patients who have acute problems from those with
chronic elevations from other causes. Using the fourth-
generation cTnT assay, approximately 0.7% of patients in
the general population have modest elevations 99th per-
centile URL (11). In the same population, this number was
2% with the hs-cTnT assay (6). Of that number, only half
had documentation (even with imaging) of cardiac abnor-
malities. If the prevalence of a positive cTnT is 2% in the
general population, it will likely be 10% or 20% in the
emergency department (ED) and even higher in hospitalized
patients, as these patients often have cardiac comorbidities.
Measurement of changes in hs-cTn over time ( hs-cTn)
mproves the specificity of hs-cTn for the diagnosis of acute
ardiac injury (12,13). However, it does so at the cost of
ensitivity. With contemporary assays, differences in analyt-
cal variation have been used to define an increasing pattern.
t elevated values, CV for most assays is in the range of 5%
o 7%, so a change of 20% ensures that a given change is not
aused by analytical variation alone (10). At values near the
9th percentile URL, higher change values are necessary
13). The situation with hs-cTn assays is much more
omplex, as the following outline shows:
. Change criteria are unique for each assay.
. It will be easy to misclassify patients with coronary artery
disease who may present with a noncardiac cause of chest
pain but have elevated values. They could be having
unstable ischemia or elevations caused by structural
cardiac abnormalities and noncardiac discomfort. If hs-
Classification ofHigh-Sensitivity Cardiac Troponin AssaysTable 2 Classification fHigh-Sensitivity Cardiac Troponin Assays
Category Description
First Generation Able to measure cTn in 50%–75% of a reference
population
Second Generation Able to measure cTn in 75%–95% of a reference
population
Third Generation Able to measure cTn in more than 95% of a reference
population.
Adapted from Apple and Collinson (3).cTn is rising significantly, the issue is easy but if the
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made. If so, some patients may be included as having
AMI without a changing pattern. This occurred in 14%
patients studied by Hammarsten et al. (14). If patients
with elevated hs-cTn without a changing pattern are not
called AMI, should they be called patients with “unstable
angina and cardiac injury” or patients with structural
heart disease and noncardiac chest pain? Perhaps both
exist?
. The release of biomarkers is flow-dependent. Thus,
there may not always be rapid access to the circulation.
An area of injury distal to a totally occluded vessel (when
collateral channels close) may be different in terms of the
dynamics of hs-cTn change than an intermittently oc-
cluded coronary artery.
. Conjoint biological and analytical variation can be mea-
sured. They are assay-dependent, and the reference change
values range from 35% to 85% (2). The use of criteria less
than that (which may be what is needed clinically) will thus
likely include individuals with changes caused by conjoint
biological and analytical variation alone. This has been
shown to be the case in many patients with nonacute
cardiovascular diagnoses (14,15).
. Most evaluations have attempted to define the optimal
delta, often with receiver operator curve analysis. Such an
approach is based on the concept that sensitivity and
specificity deserve equivalent weight. But higher deltas
improve specificity more and lower ones improve sensi-
tivity and it is not clear that all physicians want the same
tradeoffs in this regard. ED physicians often prefer
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Figure 1 Relationship Between Patient Characteristics and the
Values for the 99th percentile URL go down with more rigorous screening.
Data from Collinson et al (5)
a  Have no history of vascular disease or diabetes, and not taking cardioactive d
b  Normal defined as those individuals who had no history of vascular or cardiov
were receiving no cardiac medication AND had blood pressure 140/90 mmHg; f
and no significant valvular heart disease, LVH, diastolic heart failure, or regional whigh-sensitivity so that their miss rate is low (1%) (16), owhereas hospital clinicians want increased specificity.
This tension will need to be addressed in defining the
optimal delta.
. The delta associated with AMI may be different from
that associated with other cardiac injury (14). In addi-
tion, women have less marked elevations of cTn in
response to coronary artery disease (17) and in earlier
studies were less apt to have elevated values (18). Given
their pathology is at times different, it may be that
different metrics may be necessary based on gender.
. Some groups have assumed that if a change is of a given
magnitude over 6 hours, it can be divided by 6 and the
1-h values can be used. This approach is not data driven,
and biomarker release is more likely to be discontinuous
rather than continuous (19). In addition, the values
obtained with this approach are too small to be distin-
guished from a lack of change with most assays.
These issues pose a major challenge even for defining the
deal delta change value and provide the reasons why the use
f this approach will reduce sensitivity (20,21) (Fig. 2).
In addition, there is controversy in regard to the metrics that
hould be used with high-sensitivity assays. The Australian-
ew Zealand group proposed a 50% change for hs-cTnT
or values below 53 ng/l and a 20% change above that value
22). The 20% change is much less than conjoint biological
nd analytical variation. A number of publications have
uggested the superiority of absolute  cTn compared to
relative  cTn in discriminating between AMI and non-
MI causes of elevated cTn (23–25). However, the utility
emale
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higher values (23). A recent publication by Apple et al. (26)
calculates deltas in several different ways with a contempo-
rary assay and provides a template for how to do such studies
optimally (26). If all studies were carried out in a similar
fashion, it would help immensely. In the long run, institu-
tions will need to define the approach they wish to take. We
believe this discussion is a critical one and should include
laboratory, ED, and cardiology professionals.
Distinguishing Between Type 1 and Type 2 AMI
Although  cTn is helpful in distinguishing between AMI
and nonacute causes of Tn release, it may or may not be
useful in discerning type 1 from type 2 AMI. As assay
sensitivity increases, it appears that the frequency of type 2
AMI increases. However, making this distinction is not
easy. Type 1 AMI is caused by a primary coronary event,
usually plaque rupture. It is managed acutely with aggressive
anticoagulation and revascularization (percutaneous coro-
nary intervention or coronary artery bypass) (10). Type 2
AMI typically evolves secondary to ischemia from an oxygen
demand/supply mismatch such as severe tachycardia and
hypo- or hypertension and the like, with or without a
coronary abnormality. These events usually are treated by
addressing the underlying abnormalities. They are particu-
larly common in patients who are critically ill and those who
are postoperative (27). However, autopsy studies from
patients with postoperative AMI often manifest plaque
rupture (28). Thus, the more important events, even if less
common, may be type 1 AMIs. Type 2 events seem more
common in women, who tend to have more endothelial
dysfunction, more plaque erosion, and less fixed coronary
artery disease (28–30). Additional studies are needed to
determine how best to make this clinical distinction. For
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Figure 2 Defining the Optimal Delta:
Tension Between Sensitivity and Specificity
There is a reciprocal relationship between sensitivity and specificity. With
marked percentage changes, specificity is improved at the expense of sensitiv-
ity, and at lower values, the opposite occurs. Data from Keller et al. (20).now, clinical judgment is recommended.Analytical Imprecision
in Cardiac Troponin Assays
All analytical problems will be more critical with hs-cTn
assays. Cardiac troponin I (cTnI) and cardiac troponin T
(cTnT) are measured using enzyme linked immunosorbent
assays. As with all immunoassays, quantification of hs-cTn
can be influenced by interference between reagent antibod-
ies and the analyte (cTn), leading to false-positive or
negative results (31). Autoantibodies to cTnI or cTnT are
found in 5% to 20% of individuals and can reduce detection
of cTn (32,33). Additionally, fetal cTn isoforms can be
re-expressed in diseased skeletal muscle and detected by the
cTnT assays, resulting in false-positive values (34). Several
strategies, including the use of blocking reagents, assay
redesign, and use of antibody fragments, have been used to
reduce interference (35). However, these strategies do not
completely eliminate them. Furthermore, there are differ-
ences in measured cTn values based on specimen type
(serum versus heparinized plasma versus EDTA plasma). In
addition, hemolysis may affect the accuracy of cTn measure-
ment on some platforms (37), and it is hard to avoid
especially with blood draws from peripheral IV lines, which
are common especially in intensive care units.
Ruling Out AMI
Studies evaluating the diagnostic performance of hs-cTn
assays for the early diagnosis of AMI usually define AMI on
the basis of a rising and/or falling pattern of current
generation cTn values (21,38). However, defining AMI on
the basis of the less sensitive current generation assay results
in an underestimation of the true prevalence of AMI and an
overestimation of negative predictive value of the experi-
mental assay. It also significantly shortens the time it takes
to rule in all the AMIs and thus to definitively exclude AMI
as it ignores the new AMIs more sensitively detected by the
hs-cTn assay. Thus, in the study by Hammarsten et al. (14),
the time to exclude all AMIs was 8.5 hours when all of the
AMIs detected with the high-sensitivity assay were in-
cluded, whereas others that do not include these additional
events report this can be done in 3 to 4 hours (21,29,38). In
our view, Hammarsten is correct.
This does not mean that hs-cTn cannot help in excluding
AMI. Body et al. (39) reported that patients who present
with undetectable values (less than the LOB of the hs-cTnT
assay) were unlikely to have adverse events during follow-up.
If that group of patients is added to those who present later
than 6 hours, then perhaps a significant proportion of patients
with possible acute coronary syndrome (ACS) could have that
diagnosis excluded with the initial value (40). Studies need to
continue to evaluate cTn values for at least 6 h to define the
frequency of additional AMIs detected in that manner. Using
follow-up evaluations of patients with small event rates who are
likely to have additional care during the follow-up period are
likely to be underpowered. It may be that better initial risk
1757JACC Vol. 61, No. 17, 2013 Korley and Jaffe
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Low-risk patients who have good follow-up after an ED visit
may be a group that can be released as early as 2 h after
presentation (16).
Investigating the Causes of Positive
Troponin Values in Non-AMI Patients
Elevated Tn values (including those obtained with high-
sensitivity assays) are associated with a 2-fold higher risk for
longer-term all-cause mortality and cardiovascular death
than a negative troponin values (6,42–44). This association
is dose-dependent. If values are rising, they are indicative of
acute cardiac injury. Those patients should be admitted
because the risk is often short-term. However, if the values
are stable, assuming the timing of any acute event would
allow detection of a changing pattern, the risk, although
substantive, in our view, often plays out in the longer term
(44). Many of these individuals, assuming they are doing
well clinically, can be evaluated outside of the hospital, in
our view. However, because such elevations are an indicator
of a subclinical cardiovascular injury, such evaluations
should be early and aggressive. Data from several studies
suggest that there may well be risk far below the 99th
percentile URL value. Thus, it may evolve that patients in
the upper ranges of the normal range also require some
degree of cardiovascular evaluation.
Risk Stratifying Patients With
Nonacute Coronary Syndrome Conditions
Patients who have a rising pattern of values have a higher
risk of mortality than those with negative values regardless
of the cause. Investigations are ongoing to determine how
well results from hs-cTn testing help to risk-stratify patients
with pulmonary embolism (45), congestive heart failure
(46), sepsis (47), hypertensive emergency (48), and chronic
obstructive pulmonary disease (49). Presently, the studies
suggest that cTn values classify patients into clinically
relevant risk subgroups. Studies are needed to evaluate the
incremental prognostic benefit of hs-cTn.
Conclusions
Routine use of hs-cTn assays in the United States is
inevitable. These assays hold the promise of improving the
sensitivity of AMI diagnoses, shortening the duration of
AMI evaluation and improving the risk stratification of
other noncardiac diagnoses. However, to be able to fully
realize their potential, additional studies are needed to
address the knowledge gaps we have identified. In the
interim, clinicians need to learn how to use the 99th% URL
and the concept of changing values so when the day comes
that hs-cTn assays are available, they will have experience
with the important basic concepts.Reprint requests and correspondence: Dr. Allan S. Jaffe, Car-
diovascular Division, Gonda 5, Mayo Clinic and Medical School,
200 First Street SW, Rochester, Minnesota 55905. E-mail: jaffe.
allan@mayo.edu.
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